Operating Units & Divisions
Board of Directors
Cell Systems Informatics
Neurospora & Agaricus Platforms
Endometrial Regenerative Cells
Exclusive Channel Collaborations
Intrexon Institute for Biomolecular Research
At Intrexon we are committed to building…
A Better World Through Better DNA™
Whether engineering novel therapies in health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, we are working diligently today to create a better tomorrow.
Engineering novel solutions in
to achieve improved outcomes
Building a sustainable path to produce healthy, affordable
Utilizing a proprietary bioconversion platform for efficient
Developing innovative solutions for the
Designing bio based
Engineering Microbes for Commerical Products: From Fuels & Chemicals to APIs
Precise Gene Expression:
Proprietary RheoSwitch Technology Platform
Industry Leading Reproductive Technologies
IN THE NEWS
Intrexon to Acquire Okanagan Specialty Fruits
2/27/2015 2:30:51 PM
Increasing Access to Convenient, Fresh Produce Choices for Consumers GERMANTOWN, Md. and SUMMERLAND, British Columbia, Feb. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into an agreement to acquire Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world's first non-browning apple. Through the acquisition, Intrexon expands its food programs to include trees yielding fruit that is more appetizing and convenient for consumers while providing economic benefit throughout the tree fruit supply chain. "We are committed to bringing better versions of consumers' favou...
Intrexon to Announce Fourth Quarter and Full Year 2014 Financial Results on Monday, March 2, 2015
2/23/2015 5:00:56 AM
GERMANTOWN, Md., Feb. 23, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release fourth quarter and full year 2014 financial results after the market closes on March 2, 2015. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call." Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in...
Living Biofactories in Your Prescription Bottle?
2/13/2015 5:16:05 AM
Belgium's ActoGeniX to Join Intrexon Bringing New Generation of Orally Delivered Biotherapeutics GERMANTOWN, Md. and GHENT, Belgium, Feb. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics. The proprietary TopAct™ platform developed by ActoGeniX enables the molecular engineering of food-grade microbes (Lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokin...
Intrexon Announces Closing of $116 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
1/27/2015 7:06:18 AM
GERMANTOWN, Md., Jan. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 562,500 shares of common stock at the public offering price of $27.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Intrexon to 4,312,500 shares and increased the total gross proceeds raised in the offering to approximately $116.4 million, before deducting the underwriting discounts, commissions and estimated expenses. J.P. Morgan and B...